NEW YORK (GenomeWeb) – Canadian life sciences firm DiagnoCure announced today that its board has approved a plan to voluntarily dissolve the company and liquidate its assets.

"The board of directors of DiagnoCure has determined that the liquidation and dissolution is advisable and in the best interest of the corporation and its shareholders," DiagnoCure Chairman Jacques Simoneau said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.